<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05125367</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV 2021-03</org_study_id>
    <nct_id>NCT05125367</nct_id>
  </id_info>
  <brief_title>Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease</brief_title>
  <acronym>BEST Extended</acronym>
  <official_title>Ten-Year Outcomes of Randomized Comparison of Coronary Artery Bypass Surgery and Everolimus-Eluting Stent Implantation in the Treatment of Patients With Multivessel Coronary Artery Disease: The BEST Extended 10 Y Follow-up</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the BEST extended 10Y follow-up study is to compare the safety and&#xD;
      effectiveness of coronary stent implantation using everolimus-eluting balloon-expandable&#xD;
      stents with bypass grafting for the treatment of multivessel coronary artery disease at&#xD;
      minimum of 10 years follow-up.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 30, 2021</start_date>
  <completion_date type="Anticipated">October 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The composite event</measure>
    <time_frame>10-year</time_frame>
    <description>all-cause mortality, myocardial infarction, or target vessel revascularization (TVR)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All-cause mortality</measure>
    <time_frame>10-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial infarction</measure>
    <time_frame>10-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization (TVR)</measure>
    <time_frame>10-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stent thrombosis</measure>
    <time_frame>10-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <time_frame>10-year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatal bleeding</measure>
    <time_frame>10-year</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">880</enrollment>
  <condition>Multivessel Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>multivessel coronary artery disease</arm_group_label>
    <description>From BEST trial study population_NCT00997828</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>coronary stent implantation</intervention_name>
    <description>coronary stent implantation using everolimus-eluting balloon expandable stents</description>
    <arm_group_label>multivessel coronary artery disease</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>bypass grafting</intervention_name>
    <description>coronary artery bypass graft</description>
    <arm_group_label>multivessel coronary artery disease</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        The BEST trial study population: patients with multivessel coronary artery disease treated&#xD;
        by coronary stent implantation using everolimus-eluting balloon expandable stents or the&#xD;
        bypass grafting&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18 years or older&#xD;
&#xD;
          2. Angiographically confirmed multivessel coronary artery disease [critical (&gt;70%)&#xD;
             lesions in at least two major epicardial vessels (â‰¥ 2.0mm in diameter) at least two&#xD;
             separate coronary artery territories (the right coronary artery (RCA), left circumflex&#xD;
             artery (LCX) and left anterior descending (LAD)] and are expected to be equally&#xD;
             treatable with PCI(Percutaneous Coronary Intervention) or CABG(coronary artery bypass&#xD;
             graft) by interventionalists and surgeons at the investigating site.&#xD;
&#xD;
          3. Indication for revascularization based upon symptoms of angina and/or objective&#xD;
             evidence of myocardial ischemia&#xD;
&#xD;
          4. Geographically accessible and willing to come in for required study visits&#xD;
&#xD;
          5. Signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The patient has a known hypersensitivity or contraindication to any of the following&#xD;
             medications:&#xD;
&#xD;
               -  Heparin&#xD;
&#xD;
               -  Aspirin&#xD;
&#xD;
               -  Both Clopidogrel and TIclopidine&#xD;
&#xD;
               -  Sirolimus, paclitaxel, ABT 578&#xD;
&#xD;
               -  Stainless steel and/or&#xD;
&#xD;
               -  Contrast media (patients with documented sensitivity to contrast which can be&#xD;
                  effectively pre-medicated with steroids and diphenhydramine [e.g. rash] may be&#xD;
                  enrolled. Patients with true anaphylaxis to prior contrast media, however, should&#xD;
                  not be enrolled).&#xD;
&#xD;
          2. Severe congestive heart failure (class III or IV according to New York Heart&#xD;
             Association (NYHA) Functional Classification, or pulmonary edema) at the time of&#xD;
             enrollment. The degree of left ventricular ejection fraction is not considered as an&#xD;
             index of exclusion.&#xD;
&#xD;
          3. Planned simultaneous surgical procedure unrelated to coronary revascularization (e.g.&#xD;
             valve repair/replacement, aneurysmectomy, carotid endarterectomy or carotid stent).&#xD;
&#xD;
          4. Prior CABG surgery&#xD;
&#xD;
          5. Prior PCI with DES implantation within 1 year&#xD;
&#xD;
          6. Two or more chronic total occlusions in major coronary territories&#xD;
&#xD;
          7. Acute ST-elevation myocardial infarction(Q-wave) within 72 hours prior to enrollment&#xD;
             requiring revascularization.&#xD;
&#xD;
          8. Abnormal creatine kinase (CK &gt; 2x normal) and/or abnormal CK-MB levels and/or elevated&#xD;
             Troponin levels at time of randomization. When the cardiac enzyme is returned to&#xD;
             normal, those can be enrolled.&#xD;
&#xD;
          9. Previous stroke within 6 months or patients with stroke at more than 6 months with&#xD;
             significant residual neurologic involvement.&#xD;
&#xD;
         10. Extra-cardiac illness that is expected to limit survival to less than 2 years; e.g.&#xD;
             oxygen-dependent chronic obstructive pulmonary disease, active hepatitis or&#xD;
             significant hepatic failure, severe renal disease.&#xD;
&#xD;
         11. Prior history of significant bleeding (within the previous 6 months) that might be&#xD;
             expected to occur during CABG or PCI/DES(drug eluting stent) related anticoagulation.&#xD;
&#xD;
         12. Contraindication either CABG or PCI/DES because of a coexisting clinical condition&#xD;
&#xD;
         13. Intolerance or contraindication to aspirin or both clopidogrel and ticlopidine&#xD;
&#xD;
         14. Suspected pregnancy.&#xD;
&#xD;
         15. Concurrent enrollment in another clinical trial&#xD;
&#xD;
         16. Left main stenosis (at least 50% diameter stenosis)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Jung-min Ahn, MD</last_name>
    <phone>82230105904</phone>
    <email>drjmahn@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jung-hee Ham, Project leader</last_name>
    <email>cvcrc5@amc.seoul.kr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 8, 2021</study_first_submitted>
  <study_first_submitted_qc>November 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 18, 2021</study_first_posted>
  <last_update_submitted>November 8, 2021</last_update_submitted>
  <last_update_submitted_qc>November 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD, Heart Institute, Asan Medical Center,University of Ulsan,College of Medicine, CardioVascular Research Foundation, Korea</investigator_title>
  </responsible_party>
  <keyword>multivessel coronary artery disease</keyword>
  <keyword>percutaneous coronary intervention</keyword>
  <keyword>coronary artery bypass graft</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

